BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Campbell PT, VanWagner LB, Colangelo LA, Lewis CE, Henkel A, Ajmera VH, Lloyd-Jones DM, Vaughan DE, Khan SS. Association between plasminogen activator inhibitor-1 in young adulthood and nonalcoholic fatty liver disease in midlife: CARDIA. Liver Int 2020;40:1111-20. [PMID: 32090434 DOI: 10.1111/liv.14417] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kashiwagi R, Sato R, Masumoto M, Yoshino M, Tanaka H. AS3288802, a highly selective antibody to active plasminogen activator inhibitor-1 (PAI-1), exhibits long efficacy duration in cynomolgus monkeys. Biologicals 2020;67:21-8. [PMID: 32828642 DOI: 10.1016/j.biologicals.2020.08.001] [Reference Citation Analysis]
2 Gidaro A, Manetti R, Delitala AP, Salvi E, Bergamaschini L, Vidili G, Castelli R. Prothrombotic and Inflammatory Markers in Elderly Patients with Non-Alcoholic Hepatic Liver Disease before and after Weight Loss: A Pilot Study. J Clin Med 2021;10:4906. [PMID: 34768440 DOI: 10.3390/jcm10214906] [Reference Citation Analysis]
3 Shroff H, VanWagner LB. Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. Curr Hepatol Rep. 2020;19:315-326. [PMID: 33585157 DOI: 10.1007/s11901-020-00530-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]